RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.- 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304, **Website**- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date: 19.05.2018

Head-Listing & Compliance **BSE Limited**, Phiroze Jeejeebhoy Towers, Dalal Street, Fort Mumbai- 400001

Scrip Code: 531207

Sub: <u>Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

Dear Sir/Madam,

This is to inform you that Board of Directors of the Company in their meeting held today, i.e. Saturday, 19th February, 2018 (commenced at 12:30 P.M. and concluded at 04:30 P.M.), have considered and approved, inter-alia, the following business(s):

- 1. Consideration and Approval of the Audited Standalone Financial Results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter and year ended 31st March, 2018. (Copy Enclosed)
- **2.** The Board considered and took on record, the Audit Report on Financial Results for the quarter and year ended 31st March, 2018 as placed by the Statutory Auditor of the Company. (**Copy Enclosed**)
- **3.** Declaration of unmodified opinion on Auditor's Report on annual financial results for the quarter and year ended 31st March, 2018. (**Copy Enclosed**)
- **4.** The Board had appointed M/s Jain P & Associates, Practicing Company Secretaries, as Secretarial Auditor for the financial year 2017-18.
- **5.** The Board took note of Statement of Investor Complaints/Grievances given Under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended31st March, 2018.

Kindly take the above information on your records.

Sincerely,

For Raymed Labs Limited

Ajai Goyal Whole Time Director DIN: 02636418

Add: 103 Emperor 1, Supertech Emerald Court,

Sector 93A Noida, UP – 201304

RAYMED LABS LIMITED

REGD. OFFICE: 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304
Phone: 0120-2426900, 9412700300;
E-mail: raymedlabs@rediffmail.com; Website: www.raymedlab.com, CIN: L24111UP1992PLC014240

Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2018 Amt. (In Lakhs)

Statement of Standarone Addition Financial Results for the Quarter and Tear ended March 31, 2016 Amt. (In Lakis						
	Quarter Ended			Year Ended		
Particulars	Quarter ended 31-03-2018	Preceding 3 month ended 31-12-2017	Corresponding 3 month ended 31-03-207	Year to date figures for the Curent year ended on 31-03-2018	Year to date figures for the previous year period ended on 31-03-2017	
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
I. Revenue from Operations	0.00	0.00	0.00	0.00	0.00	
II. Other Income	0.30	0.30	0.30	1.20	1.20	
III. Total Income (I +II)	0.30	0.30	0.30	1.20	1.20	
IV. Expenses						
Cost of Material Consumed	0.00	0.00	0.00	0.00	0.00	
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00	
Changes in inventories of finished goods, Work-in-						
progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	
Employee Benefits Expenses	0.23	0.23	0.23	1.06	1.22	
Finance Costs	0.00	0.00	0.00	0.00	0.00	
Depreciation and amortisation expenses	0.17	0.17	0.05	0.68	0.71	
Other Expenses	0.79	0.20	0.38	2.26	1.98	
Total Expenses (IV)	1.19	0.60	0.66	4.00	3.91	
V. Profit/(Loss) before exceptional items and tax (III-IV)	-0.89	-0.30	-0.36	-2.80	-2.71	
VI. Exceptional items	0.00	0.00	0.00	2.88	2.29	
VII. Profit/(Loss) before tax (V-VI)	-0.89	-0.30	-0.36	-5.68	-5.00	
VIII. Tax Expense						
(1) Current tax	0.00	0.00	0.00	0.00	0.00	
(2) Deferred tax (3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00	
IX. Profit/(Loss) for the period from continuing			0.00	0.00	0.00	
operations (VII-VIII)	-0.89	-0.30	-0.36	-5.68	-5.00	
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	
XII. Profit/(Loss) from Discontinued operations	0.00	0.00	0.00	0.00	0.00	
(after tax) (X-XI)						
XIII. Profit/(Loss) for the period (IX+XII)	-0.89	-0.30	-0.36	-5.68	-5.00	
XIV. Other Comprehensive Income						
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	
(ii) Income tax relating to items that will not be	0.00	0.00	0.00	0.00	0.00	
reclassified to profit or loss						
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	
XV. Total Comprehensive Income for the period						
(XIII+XIV)						
(Comprising Profit (Loss) and Other Comprehensive	-0.89	-0.30	-0.36	-5.68	-5.00	
Income for the Period)			<u></u>			
XVI. Earnings per equity share (for continuing					-	
operation):						
(1) Basic	-0.021	0.007	-0.008	-0.133	-0.117	
(2) Diluted	-0.021	0.007	-0.008	-0.133	-0.117	
XVII. Earnings per equity share (for discontinued operation):						
(1) Basic	0.00	0.00	0.00	0.00	0.00	
(2) Diluted	0.00	0.00	0.00	0.00	0.00	
XVIII. Earnings per equity share (for discontinued		,,,,,				
& continuing operations)						
(1) Basic	-0.021	0.007	-0.008	-0.133	-0.117	
(2) Diluted	-0.021	0.007	-0.008	-0.133	-0.117	

Notes:

- (1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 19th, May 2018. The Statutory Auditors have carried out their Audit of the above results.

 (2) The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- (3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

 (4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification

- (5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.

 (6) Reconciliation of Net Profit as previously reported under GAAP and IND AS for the period as reported above has been given in Annexure-I

Particulars	Quarter ended 31.03.2017	Year ended 31.03.2017
Reconciliation of Net Profit as previously reported in GAAP and IND		
Net Profit as reported under previous GAAP	-0.36	-5.00
Financial Cost recognised on fair value of financial liabilities	Nil	Nil
Impact of adjustment in revenue from operations	Nil	Nil
Impact of adjustment in trade receivables	Nil	Nil
Impact of measurement of certain receivables at fair value	Nil	Nil
Tax Adjustments	Nil	Nil
Net profit as per IND AS	-0,36	-5.00

For Raymed Labs Limited

Ajai Goyal Whole Time Director DIN: 02636418 Add: 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304

Date: 19.05.2018 Place: Noida

RAYMED LABS LIMITED

REGD. OFFICE: 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304 Phone: 0120-2425900, 9412700300; E-mail: raymedlabs@rediffmail.com; Website: www.raymedlab.com, CIN: L24111UP1992PLC014240

CIN : LZ41110P1992PLC014Z40 Standalone Statement of Assets and Liabilities				
Particulars	Assets and Liabilities			
	Figures at the end of current reporting period i.e. 31/03/2018	Figures at the end of previous reporting period i.e. 31/03/2017		
	(Audited)	(Audited)		
ASSETS				
Non current assets				
(a) Property, Plant and Equipment	17.92	18.59		
(b) Capital Work in Progress	-			
(c) Investment Property				
(d) Goodwill				
(e) Other Intangible Assets				
(f) Intengible assets under development				
(g) Biological Assets other than bearer plants				
(h) Financials Assets-				
(i) Investments				
(ii) Trade Receivables				
(iii) Loans				
(iv) Other(to be specified)				
(i) Deferred tax assets (net)				
(j) Other non-current assets				
Current Assets				
(a) Inventories				
(b) Financials Assets (i) Investments				
(ii) Trade receivables	2.40			
(iii) Cash and cash equivalents	2.49 0.03	2.4 0.0		
(iv) Bank Balance other than (iii) above				
(v) Loans	0.03	0.0		
(vi) Otheres (to be specified)	6.10	6.1		
(c) Current tex Assets	0.45	0.4		
(d) Other current Assets				
TOTAL ASSETS	27.02	27.6		
EQUITY AND LIABILITES	27.02	27.0		
Equity-				
(a) Equity Share Capital	427.35	427.3		
(b) Other Equity	-614.84	-609.1		
Liabliaties				
Non -Current liabilites				
(a) Financials Liablities				
(i) Borrowings				
(ii) Trade Payable				
(iii) Other Financial liablities (other than specified in item (b) to be specified				
(b) Provisions				
(c) Deffered Tax Liabilites (net)				
(d) Other Non-Current Liablities				
Current Liablities				
(a) Financials Liablities				
(i) Borrowings	198.80	197.9		
(ii) Trade Payables	4.80	4.1		
(iii) Other Financial liablities (other than	4.80	4.1		
specified in item (c) tobe specified	5.00	5.0		
(b) Other current liabilities	5.92	2.4		
(c) provisions	3.32	2.1		
(d) Current Tax Liablitries				
TOTAL EQUITY AND LIABILITES	27.02	27.6		

(1) Reconciliation of Net Profit as previously reported under GAAP and IND AS for the period as reported above has been given in Annexure-II

	Year Ended
Particular	31.03.2017
Total Equity as per GAAP	-181.82
IND AS Adjustments	Nil
Total Equity as per IND AS	-181.82

For Raymed Labs Limited

Ajai Goyal Whole Time Director DIN: 02636418 Add: 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304

Date: 19.05.2018 Place: Noida



A.Kay Mehra & Co. CHARTERED ACCOUNTANTS

114 (Basement), Mall Road, Kingsway Camp, Delhi-110009

Tel. No. : 011-42461274, 9891295255, 9818708294 E-mail : akmca1969@gmail.com Website : www.akmca.in

Independent Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors
Raymed Labs Limited
703, Aster 7, Supertech Emerald Court,
Sector 93A, Noida- 201304

- We have audited the accompanying Statement of Financial Results of Raymed Labs Limited ("The Company") for the quarter and year ended 31stMarch, 2018 ("The Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related Ind AS financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such financial statements.
- 3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

HEAD OFFICE: 120/128, LAJPAT NAGAR, KANPUR-208 005, PH. No.: 0512-2240909, 9956358976
BRANCH OFFICES: 114,(BASEMENT) MALL ROAD, KINGSWAY CAMP, DELHI-110009 & C-32, SECTOR-14, NOIDA-201301



A.Kay Mehra & Co. CHARTERED ACCOUNTANTS

114 (Basement), Mall Road, Kingsway Camp, Delhi-110009

Tel. No.: 011-42461274, 9891295255, 9818708294

E-mail: akmca1969@gmail.com Website: www.akmca.in

4. In our opinion and to the best of our information and according to the explanations given to us, the these quarterly and year to date financial results:

- i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
- ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net loss and other financial information of the Company for the quarter and year ended 31st March, 2018.
- 5. The Statement includes the results for the quarter ended March 31, 2018 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the of the current year which are subject limited review by us.

For A Kay Mehra & Co. Chartered Accountants

(F.R.N. 050004C)

CA Deepak Suneja

Partner

(Membership No. 501957)

Place: New Delhi Date: May 19, 2018

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.- 103 Emperor 1, Supertech Emerald Court, Sector 93A Noida, UP – 201304, **Website**- www.raymedlab.com **E-mail**- raymedlabs@rediffmail.com, **Phone no**. - 0120-2426900, 9412700300

Date: 19.05.2018

The Head- Listing Compliance **BSE Limited**, Phiroze Jeejeebhoy Towers, Dalal Street, Fort Mumbai- 400001

Sub: Declaration on Audit Report for the year ended 31st March, 2018

Dear Sir/Madam,

We hereby declare, on behalf of **Raymed Labs Limited** that Audit report in respect to Annual Audited financial Results for the period ended 31st March, 2018 submitted by A Kay Mehra Co., Statutory Auditor of the Company is with unmodified opinion of the Statutory Auditor.

Sincerely,

For Raymed Labs Limited

Ajai Goyal Whole Time Director DIN: 02636418

Add: 103 Emperor 1, Supertech Emerald Court,

Sector 93A Noida, UP - 201304